Literature DB >> 19172239

Temsirolimus in patients with advanced renal cell carcinoma: an overview.

Shailender Bhatia1, John A Thompson.   

Abstract

Treatment of patients with advanced renal cell carcinoma (RCC) has changed dramatically with the advent of targeted therapeutics. Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), has proven beneficial in the treatment of advanced RCC with poor prognosis. The rationale for mTOR inhibitors in treatment of RCC, the pharmacokinetics and toxicities of temsirolimus, landmark clinical trials of temsirolimus in advanced RCC, and the indications for its use in the treatment of RCC are reviewed here. The status of temsirolimus in the rapidly evolving therapeutic landscape of advanced RCC is also discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19172239     DOI： 10.1007/s12325-008-0138-3

Source DB:  PubMed          Journal:  Adv Ther        ISSN： 0741-238X            Impact factor:   3.845


  7 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders.

Authors:  Jérémie Neasta; Sami Ben Hamida; Quinn Yowell; Sebastien Carnicella; Dorit Ron
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 3.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

Review 4.  Recent updates in renal cell carcinoma.

Authors:  W Kimryn Rathmell; Paul A Godley
Journal:  Curr Opin Oncol       Date:  2010-05       Impact factor: 3.645

5.  Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

Authors:  Patrick A Singleton; Nurbek Mambetsariev; Frances E Lennon; Biji Mathew; Jessica H Siegler; Liliana Moreno-Vinasco; Ravi Salgia; Jonathan Moss; Joe Gn Garcia
Journal:  J Angiogenes Res       Date:  2010-02-19

6.  An emerging role for the Mammalian target of rapamycin in "pathological" protein translation: relevance to cocaine addiction.

Authors:  Christopher V Dayas; Doug W Smith; Peter R Dunkley
Journal:  Front Pharmacol       Date:  2012-02-06       Impact factor: 5.810

Review 7.  Roles of pathologists in molecular targeted cancer therapy.

Authors:  Robert Y Osamura
Journal:  J Cell Mol Med       Date:  2009-11-04       Impact factor: 5.310
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.